Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: Prediction of in vivo drug interactions

References

• Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. 2001. Psychiatric disorders and associated and predictive factors in patients with unresectable non small cell lung carcinoma: A longitudinal study. Cancer 92:2609–2622.
   PubMed Web of Science ®Google Scholar
• Altamura AC, Moro AR, Percudani M. 1994. Clinical pharmacokinetics of fluoxetine. Clinical Pharmacokinetics 26:201–214.
   PubMed Web of Science ®Google Scholar
• Apple FS, Bandt CM. 1988. Liver and blood postmortem tricyclic antidepressant concentrations. American Journal of Clinical Pathology 89:794–796.
   PubMed Web of Science ®Google Scholar
• Araki K, Yasui N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K. 2004. Inhibition of the metabolism of etizolam by itraconazole in humans: Evidence for the involvement of CYP3A4 in etizolam metabolism. European Journal of Clinical Pharmacology 60:427–430.
   PubMed Web of Science ®Google Scholar
• Bajpai M, Roskos LK, Shen DD, Levy RH. 1996. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metabolism and Disposition 24:1401–1403.
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metabolism and Disposition 31:289–293.
   PubMed Web of Science ®Google Scholar
• Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. 1992. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. British Journal of Clinical Pharmacology 33:521–523.
   PubMed Web of Science ®Google Scholar
• Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. 1993. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European Journal of Clinical Pharmacology 44:349–355.
   PubMed Web of Science ®Google Scholar
• Brown CS, Farmer RG, Soberman JE, Eichner SF. 2004. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clinical Pharmacokinetics 43:33–56.
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. 1999. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 37:177–193.
   Google Scholar
• Campbell NP, Kelly JG, Adgey AA, Shanks RG. 1978. The clinical pharmacology of mexiletine. British Journal of Clinical Pharmacology 6:103–108.
   PubMed Web of Science ®Google Scholar
• Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JA, Berecz R, Duran M, Benitez J. 1999. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. Journal of Clinical Psychopharmacology 19:494–499.
   PubMed Web of Science ®Google Scholar
• Chakraborty BS, Midha KK, McKay G, Hawes EM, Hubbard JW, Korchinski ED, Choc MG, Robinson WT. 1989. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: A dose proportionality study. Journal of Pharmaceutical Sciences 78:796–801.
   PubMed Web of Science ®Google Scholar
• Cooper SF, Dugal R, Elie R, Albert JM. 1979. Metabolic interaction between amitriptyline and perphenazine in psychiatric patients. Progress in Neuropsychopharmacology 3:369–376.
   PubMedGoogle Scholar
• DeVane CL, Liston HL, Markowitz JS. 2002. Clinical pharmacokinetics of sertraline. Clinical Pharmacokinetics 41:1247–1266.
   PubMed Web of Science ®Google Scholar
• Dinovo EC, Bost RO, Sunshine I, Gottschalk LA. 1978. Distribution of thioridazine and its metabolites in human tissues and fluids obtained postmortem. Clinical Chemistry 24:1828–1830.
   PubMed Web of Science ®Google Scholar
• Eap CB, Guentert TW, Schaublin-Loidl M, Stahl M, Koeb L, Powell K, Baumann P. 1996. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clinical Pharmacology and Therapeutics 59:322–331.
   PubMed Web of Science ®Google Scholar
• Fang J, Baker GB, Silverstone PH, Coutts RT. 1997. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cellular and Molecular Neurobiology 17:227–233.
   PubMed Web of Science ®Google Scholar
• Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brosen K. 1999. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 9:55–60.
   PubMedGoogle Scholar
• Goldney RD, Phillips PJ, Fisher U, Wilson DH. 2004. Diabetes, depression, and quality of life: A population study. Diabetes Care 27:1066–1070.
   PubMed Web of Science ®Google Scholar
• Gram LF, Overo K, Kirk L. 1974. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man. American Journal of Psychiatry 131:863–866.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. 1997. Role of cytochrome P450 enzymes in drug-drug interactions. Advance in Pharmacology 43:7–35.
   PubMedGoogle Scholar
• Harten J. 1995. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 29:1–9.
   PubMedGoogle Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. 2003. Prediction of the in vivo interaction between midazolam and macro-lides based on in vitro studies using human liver microsomes. Drug Metabolism and Disposition 31:945–954.
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Okuda H, Ogura K, Watabe T, Muro K, Sugiyama Y. 2000. Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: Inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl) uracil. Drug Metabolism and Disposition 28:467–474.
   PubMed Web of Science ®Google Scholar
• Kato K, Yasui N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K. 2003. Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Therapeutic Drug Monitoring 25:473–477.
   PubMed Web of Science ®Google Scholar
• Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH. 1989. A review of themetabolism and pharmacokinetics of paroxetine in man. Acta Psychiatrica Scandinavica Supplementum 350:60–75.
   PubMedGoogle Scholar
• Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. 1994. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology 47:1969–1979.
   Google Scholar
• Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Hone T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y. 1997. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 280:927–233.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. 1999. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metabolism and Disposition 27:763–766.
   PubMed Web of Science ®Google Scholar
• Kugaya A, Akechi T, Okuyama T, Nakano T, Mikami I, Okamura H, Uchitomi Y. 2000. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817–2823.
   PubMed Web of Science ®Google Scholar
• Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. 1997. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clinical Pharmacology and Therapeutics 62:145–156.
   PubMed Web of Science ®Google Scholar
• Labbe L, Turgeon J. 1999. Clinical pharmacokinetics of mexiletine. Clinical Pharmacokinetics 37:361–384.
   PubMed Web of Science ®Google Scholar
• Lane RM. 1996. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. International Clinical Psychopharmacology 11:31–61.
   PubMed Web of Science ®Google Scholar
• Levine B, Jenkins AJ, Smialek JE. 1994. Distribution of sertraline in postmortem cases. Journal of Analytical Toxicology 18:272–274.
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. 1998. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics 35:361–390.
   PubMed Web of Science ®Google Scholar
• Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, Obach RS. 2000. (R)-, (5)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metabolism and Disposition 28:1187–1191.
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. 2000. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metabolism and Disposition 28:1031–1037.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kobayashi K, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. 1998. Involvement of CYP1A2 in mexiletine metabolism. British Journal of Clinical Pharmacology 46:55–62.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yokoi T. 1999. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 29:1191–1202.
   PubMed Web of Science ®Google Scholar
• Nyberg G, Axelsson R, Martensson E. 1978. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. European Journal of Clinical Pharmacology 14:341–350.
   PubMed Web of Science ®Google Scholar
• Okamura H, Watanabe T, Narabayashi M, Katsumata N, Ando M, Adachi I, Akechi T, Uchitomi Y. 2000. Psychological distress following first recurrence of disease in patients with breast cancer: Prevalence and risk factors. Breast Cancer Research and Treatment 61:131–137.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Correia MA. 1995. Inhibition of cytochrome P450 enzymes. In: PR Ortiz de Montellano, editor. Cytochrome P450 structure, mechanism and biochemistry. New York: Plenum. pp 305–366.
   Google Scholar
• Otani M, Fukuda T, Naohara M, Maune H, Senda C, Yamamoto I, Azuma J. 2003. Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers. European Journal of Clinical Pharmacology 59:395–399.
   PubMed Web of Science ®Google Scholar
• Paczkowski D, Sadowski Z, Filipek M, Kolinski P. 1990. Pharmacokinetics of mexiletine and its metabolites, hydroxyrnethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects. Polish Journal of Pharmacology and Pharmacy 42:365–375.
   PubMedGoogle Scholar
• Pan LP, Wijnant P, Vriendt C, Rosseel MT, Belpaire FM. 1997. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. British Journal of Clinical Pharmacology 44:557–564.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. 1998. Debate resolved: There are differential effects of serotonin selective reuptake inhibitors on cytochrome P450 enzymes. Journal of Psychopharmacology 12:S89–97.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. 1996. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. Journal of Pharmacology and Experimental Therapeutics 276:658–666.
   PubMed Web of Science ®Google Scholar
• Sallee FR, Pollock BG. 1990. Clinical pharmacokinetics of imipramine and desipramine. Clinical Pharmacokinetics 18:346–364.
   PubMed Web of Science ®Google Scholar
• Segel IH, editor. 1993. Rapid equilibrium partial and mixed type inhibition. In: Enzyme kinetics. New York: Wiley-Interscience. pp 161–226.
   Google Scholar
• Silverman RB, editor. 1988. Mechanism-based enzyme inactivation. In: Chemistry and enzymology. Vol. 1. Boca Raton, FL: CRC Press. pp 3–30.
   Google Scholar
• Skjelbo E, Brosen K. 1992. Inhibitors of imipramine metabolism by human liver microsomes. British Journal of Clinical Pharmacology 34:256–261.
   PubMed Web of Science ®Google Scholar
• Uchitomi Y, Mikami I, Nagai K, Nishiwaki, Y, Akechi T, Okamura H. 2003. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. Journal of Clinical Oncology 21:69–77.
   PubMed Web of Science ®Google Scholar
• Vanderheeren FA, Muusze RG. 1977. Plasma levels and half lives of thioridazine and some of its metabolites I. High doses in young acute schizophrenics. European Journal of Clinical Pharmacology 11:135–140.
   PubMed Web of Science ®Google Scholar
• Vermeulen T. 1998. Distribution of paroxetine in three postmortem cases. Journal of Analytical Toxicology 22:541–544.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. 1995. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. Journal of Clinical Psychopharmacology 15:125–131.
   PubMed Web of Science ®Google Scholar